153 related articles for article (PubMed ID: 38001703)
1. Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.
de Boer JW; Keijzer K; Pennings ERA; van Doesum JA; Spanjaart AM; Jak M; Mutsaers PGNJ; van Dorp S; Vermaat JSP; van der Poel MWM; van Dijk LV; Kersten MJ; Niezink AGH; van Meerten T;
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001703
[TBL] [Abstract][Full Text] [Related]
2. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.
Pennisi M; Sanchez-Escamilla M; Flynn JR; Shouval R; Alarcon Tomas A; Silverberg ML; Batlevi C; Brentjens RJ; Dahi PB; Devlin SM; Diamonte C; Giralt S; Halton EF; Jain T; Maloy M; Mead E; Palomba ML; Ruiz J; Santomasso B; Sauter CS; Scordo M; Shah GL; Park JH; Yanez San Segundo L; Perales MA
Blood Adv; 2021 Sep; 5(17):3397-3406. PubMed ID: 34432870
[TBL] [Abstract][Full Text] [Related]
3. Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy.
Zhao Y; Zhang X; Zhang M; Guo R; Zhang Y; Pu Y; Zhu H; Liu P; Zhang Y; He X; Lyu C; Lyu H; Xiao X; Zhao M
Ann Hematol; 2024 Mar; 103(3):969-980. PubMed ID: 38214708
[TBL] [Abstract][Full Text] [Related]
4. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity.
Greenbaum U; Strati P; Saliba RM; Torres J; Rondon G; Nieto Y; Hosing C; Srour SA; Westin J; Fayad LE; Lee HJ; Iyer SP; Nair R; Nastoupil LJ; Parmar S; Rodriguez MA; Samaniego F; Steiner RE; Wang M; Pinnix CC; Flowers CR; Tummala S; Ramdial JL; Yalniz FF; Hawkins M; Rezvani K; Champlin RE; Shpall EJ; Neelapu SS; Kebriaei P; Ahmed S
Blood Adv; 2021 Jul; 5(14):2799-2806. PubMed ID: 34264268
[TBL] [Abstract][Full Text] [Related]
5. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study.
Korell F; Penack O; Mattie M; Schreck N; Benner A; Krzykalla J; Wang Z; Schmitt M; Bullinger L; Müller-Tidow C; Dreger P; Luft T
Front Immunol; 2022; 13():877477. PubMed ID: 35464403
[TBL] [Abstract][Full Text] [Related]
6. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
[TBL] [Abstract][Full Text] [Related]
7. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Holtzman NG; Xie H; Bentzen S; Kesari V; Bukhari A; El Chaer F; Lutfi F; Siglin J; Hutnick E; Gahres N; Ruehle K; Ahmad H; Shanholtz C; Kocoglu MH; Badros AZ; Yared JA; Hardy NM; Rapoport AP; Dahiya S
Neuro Oncol; 2021 Jan; 23(1):112-121. PubMed ID: 32750704
[TBL] [Abstract][Full Text] [Related]
8. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
9. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
10. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.
Strati P; Nastoupil LJ; Westin J; Fayad LE; Ahmed S; Fowler NH; Hagemeister FB; Lee HJ; Iyer SP; Nair R; Parmar S; Rodriguez MA; Samaniego F; Steiner RE; Wang M; Pinnix CC; Adkins S; Claussen CM; Martinez CS; Hawkins MC; Johnson NA; Singh P; Mistry HE; Horowitz S; George S; Feng L; Kebriaei P; Shpall EJ; Neelapu SS; Tummala S; Chi TL
Blood Adv; 2020 Aug; 4(16):3943-3951. PubMed ID: 32822484
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity.
De Matteis S; Dicataldo M; Casadei B; Storci G; Laprovitera N; Arpinati M; Maffini E; Cortelli P; Guarino M; Vaglio F; Naddeo M; Sinigaglia B; Zazzeroni L; Guadagnuolo S; Tomassini E; Bertuccio SN; Messelodi D; Ferracin M; Bonafè M; Zinzani PL; Bonifazi F
Front Immunol; 2022; 13():1058126. PubMed ID: 36726971
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy.
Winkelmann M; Blumenberg V; Rejeski K; Quell C; Bücklein VL; Ingenerf M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
Ann Hematol; 2024 Jan; 103(1):259-268. PubMed ID: 37861736
[TBL] [Abstract][Full Text] [Related]
14. Host metabolome predicts the severity and onset of acute toxicities induced by CAR T-cell therapy.
Jalota A; Hershberger CE; Patel MS; Mian A; Faruqi A; Khademi G; Rotroff DM; Hill BT; Gupta N
Blood Adv; 2023 Sep; 7(17):4690-4700. PubMed ID: 36399526
[TBL] [Abstract][Full Text] [Related]
15. Brain FDG-PET findings in chimeric antigen receptor T-cell therapy neurotoxicity for diffuse large B-cell lymphoma.
Morbelli S; Gambella M; Raiola AM; Ghiggi C; Bauckneht M; Raimondo TD; Lapucci C; Sambuceti G; Inglese M; Angelucci E
J Neuroimaging; 2023; 33(5):825-836. PubMed ID: 37291470
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
Gu T; Hu K; Si X; Hu Y; Huang H
WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
[TBL] [Abstract][Full Text] [Related]
17. Neurological management and work-up of neurotoxicity associated with CAR T cell therapy.
Möhn N; Bonda V; Grote-Levi L; Panagiota V; Fröhlich T; Schultze-Florey C; Wattjes MP; Beutel G; Eder M; David S; Körner S; Höglinger G; Stangel M; Ganser A; Koenecke C; Skripuletz T
Neurol Res Pract; 2022 Jan; 4(1):1. PubMed ID: 35000613
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
Schorr C; Forindez J; Espinoza-Gutarra M; Mehta R; Grover N; Perna F
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176053
[TBL] [Abstract][Full Text] [Related]
19. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review.
Weinstein B; Muresan B; Solano S; de Macedo AV; Lee Y; Su YC; Ahn Y; Henriquez G; Camargo C; Kim GJ; Carpenter DO
Innov Pharm; 2021; 12(4):. PubMed ID: 36033121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]